Patent US4920143A successfully refreshed from Google Patents.
US4920143A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
Assignee: BRITISH COLUMBIA A CORP OF VANCOUVER BC CANADA, University of
•
Filing: 1988-07-19
•
Granted: 1990-04-24
•
Expires: 2008-07-19
Abstract
Abstract A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
Inventors
- 👤 Julia G. Levy
- 👤 David Dolphin
- 👤 Jack K. Chow
- 👤 Ethan Sternberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 15:50
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0485; A61K41/00; A61K41/0057; A61K41/0071; A61K49/00; A61K49/001; A61K49/0013; A61K49/0017; A61K49/0019; A61K49/0021; A61K49/0036; A61K49/005; A61K49/0058; A61K51/08; A61K51/10; A61K51/1093; C; C07; C07D; C07D487/00; C07D487/22; C07D519/00; A61K2121/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
131 words
A compound of the formula ##STR7## wherein each R 1 and R 2 is independently selected from the group consisting of carbalkoxy (1-6C), alkyl (1-6C) sulfonyl, aryl sulfonyl, and aryl, and each R 3 is independently CH 2 CH 2 COOR 3' where R 3' is H or alkyl (1-6C); and R 4 is CHCH 2 , CH 2 OR 4' , CH(OR 4' )CH 3 , CH(OR 4' )CH 2 OR 4' , --CH(SR 4' )CH 3 , --CH(NR 4' 2 )CH 3 , --CH(CN)CH 3 , --CH(COOR 4' )CH 3 , --CH(OOCR 4' , )CH 3 , --CH(halo)CH 3 , and --CH(halo)CH 2 (halo), wherein R 4' is H, alkyl (1-6C), with the proviso that if R 4 is CHCH 2 , both R 3' , cannot be alkyl.
Claim 2
Dependent Claim
131 words
A compound of the formula ##STR7## wherein each R 1 and R 2 is independently selected from the group consisting of carbalkoxy (1-6C), alkyl (1-6C) sulfonyl, aryl sulfonyl, and aryl, and each R 3 is independently CH 2 CH 2 COOR 3' where R 3' is H or alkyl (1-6C); and R 4 is CHCH 2 , CH 2 OR 4' , CH(OR 4' )CH 3 , CH(OR 4' )CH 2 OR 4' , --CH(SR 4' )CH 3 , --CH(NR 4' 2 )CH 3 , --CH(CN)CH 3 , --CH(COOR 4' )CH 3 , --CH(OOCR 4' , )CH 3 , --CH(halo)CH 3 , and --CH(halo)CH 2 (halo), wherein R 4' is H, alkyl (1-6C), with the proviso that if R 4 is CHCH 2 , both R 3' , cannot be alkyl.
Claim 3
Dependent Claim
13 words
The compound of claim 1 wherein R 1 and R 2 are carbalkoxy.
Claim 4
Dependent Claim
15 words
The compound of claim 2 wherein R 1 and R 2 are carbomethoxy or carboethoxy.
Claim 5
Dependent Claim
16 words
The compound of claim 2 which is of formulae mulae 3 or 4 of FIG. 1.
Claim 6
Dependent Claim
20 words
The compound of claim 2 wherein R 4 is selected from --CHCH 2 , --CH(OH)CH 3 and --CH(halo)CH 3 .
Claim 7
Dependent Claim
19 words
The compound of claim 2 which is selected from compounds of the formula ##STR8## wherein R is alkyl (1-6C).
Claim 8
Dependent Claim
10 words
The compound of claim 5 which is of the formula
Claim 9
Dependent Claim
32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 1 in admixture with at least one pharmaceutically acceptable excipient.
Claim 10
Dependent Claim
32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 5 in admixture with at least one pharmaceutically acceptable excipient.
Claim 11
Dependent Claim
32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 6 in admixture with at least one pharmaceutically acceptable excipient.
Claim 12
Dependent Claim
32 words
A pharmaceutical composition which is useful in targeting specific biological material which composition comprises an effective amount of the compound of claim 7 in admixture with at least one pharmaceutically acceptable excipient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-23 | 1993-10-23 | 1994-04-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-23 | 1997-10-23 | 1998-04-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-23 | 2001-10-23 | 2002-04-24 | $7700.00 | Window Closed / Lapsed |